Wells Fargo & Company Harmony Biosciences Holdings, Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 18,005 shares of HRMY stock, worth $703,815. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,005
Previous 113,495
84.14%
Holding current value
$703,815
Previous $4.53 Million
86.35%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding HRMY
# of Institutions
254Shares Held
46.6MCall Options Held
119KPut Options Held
50K-
Valor Management LLC Chicago, IL6.62MShares$259 Million92.04% of portfolio
-
Black Rock Inc. New York, NY5.84MShares$228 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.73MShares$185 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.28MShares$89.1 Million0.19% of portfolio
-
State Street Corp Boston, MA1.58MShares$61.8 Million0.0% of portfolio
About Harmony Biosciences Holdings, Inc.
- Ticker HRMY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,161,400
- Market Cap $2.31B
- Description
- Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...